Benzinga

Benzinga

Benzinga

samedi, août 29

Crinetics Pharmaceuticals Inc

CRNXNASDAQ
Trade with Public
Trade with Public
$84.84
-0.01-0.01%
À la clôture: Aug 28, 5:00 PM EST
$84.97
0.130.15%
Après les heures: 6:58 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Crinetics Pharmaceuticals Financials

Crinetics Pharmaceuticals (CRNX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Crinetics Will Not Provide Updated Guidance, Withdraws Prior Outlook Following Vertex Deal Announcement

Business Outlook and Conference CallIn light of Crinetics’ July 6, 2026 announcement regarding the proposed transaction with Vertex, Crinetics will not be providing updated guidance and is withdrawing its previously
Benzinga Newsdesk

PRO
Crinetics Pharmaceuticals Q2 EPS $(1.14) Beats $(1.24) Estimate, Sales $25.118M Beat $14.840M Estimate

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.24) by 8.06 percent. This is a 7.32 percent increase over losses of $(1.23) per
Benzinga Newsdesk

Nasdaq Dips Over 300 Points as Chip Stocks Fall: Investor Sentiment Weakens, Greed Index In 'Fear' Zone

Market sentiment slightly declines as Nasdaq falls. Crinetics shares soar, Rivian shares dip. Trade deficit rises.
Avi Kapoor

PRO
Crinetics Pharmaceuticals Q1 EPS $(1.23) Beats $(1.25) Estimate, Sales $10.306M Beat $8.512M Estimate

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.23) per share which beat the analyst consensus estimate of $(1.25) by 1.6 percent. This is a 18.27 percent decrease over losses of $(1.04) per
Benzinga Newsdesk

Crinetics Pharmaceuticals Earnings Report: Q4 Overview

Benzinga Insights

PRO
Crinetics Pharmaceuticals Q4 EPS $(1.29) Beats $(1.36) Estimate, Sales $6.161M Beat $4.605M Estimate.

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(1.29) per share which beat the analyst consensus estimate of $(1.36) by 5.43 percent. This is a 46.59 percent decrease over losses of $(0.88) per
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved